QR-koda

Abemaciclib in combination with therapies for patients with metastatic breast cancer: a phase 1b study

BackgroundThe oral, selective, and potent small molecule cyclin-dependent kinases (CDK) 4/6 inhibitor (CDK4/6i) abemaciclib has demonstrated efficacy in advanced breast cancer and high-risk early breast cancer. This Phase 1b study evaluated the safety, tolerability, pharmacokinetics, and antitumor a...

Olles dieđut

Furkejuvvon:
Váldodahkkit: Sara M. Tolaney, Komal Jhaveri, Teresa Helsten, Shannon L. Puhalla, Alison Conlin, E. Claire Dees, Muralidhar Beeram, Sonya C. Chapman, Andrew Lithio, Lacey M. Litchfield, Matthew P. Goetz
Materiálatiipa: Artigo
Giella:Inglês
Almmustuhtton: Frontiers Media S.A. 2025-03-01
Ráidu:Frontiers in Oncology
Fáttát:
abemaciclib
metastatic breast cancer
CDK4
CDK6
everolimus
exemestane
Liŋkkat:https://www.frontiersin.org/articles/10.3389/fonc.2025.1555921/full
Fáddágilkorat: Lasit fáddágilkoriid
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!

Geahča maid